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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S284Purpose: Inﬂammation of synovial membrane in osteoarthritis (OA) is one
of the major signs of structure damage during disease progression.
Chondroitin sulfate (CS) is effective in the treatment of OA. Recently, CS has
shown to reduce joint swelling and effusion in OA patients in the NIH-
funded GAIT study (N Engl J Med 2006,23;354(8):795-808). The purpose of
this pilot study was to compare the effect of CS (Condrosan,Bioibérica
S.A.,Barcelona) on synovitis of OA patients vs. acetaminophen.
Methods: Synovitis (synovial hypertrophy+effusion4mm) was evaluated
by sonography in 45 patients treated with CS (800mg/day) or acetamin-
ophen (4g/day) for 6 months. Patients were followed-up until month 9 to
evaluate the carry-over effect. Synovial hypertrophy was assessed by
sonography and synovial effusion was quantiﬁed by artrhocentesis.
Symptomatic effect of both treatments was also evaluated by Lequesne
Algofunctional Index (baseline,1.5,3,6 and 9 months). Analysis of contin-
uous variables was based on analyses of covariance (ANCOVA) model.
Comparison between the two groups was obtained using an independent
sample t-test for quantitative variables or a chi-squared test for qualitative
variables. P values less than or equal to 0.05 were considered statistically
signiﬁcant for each variable.
Results: Eligible patients had clinical and radiographic evidence of OA
(Kellgren&Lawrence grade 2 and 3) with synovitis assessed by sonography.
Mean age of patients was 70.44 years. 72.09% were women. Mean BMI was
28.97. At the end of the study, CS signiﬁcantly reduced synovitis compared
to acetaminophen (p<0.01). Compared to baseline, CS treated patients
presented a 25.45% reduction of synovitis (6.641.69 vs.
4.881.69;p<0.05) and, speciﬁcally, a 61.93% reduction of synovial
hypertrophy (3.731.96 vs. 2.311.98;p<0.05). No effect on synovitis was
observed in the acetaminophen group over time. Additionaly, CS and not
acetaminophen effectively reduced functional incapacity after 6 months of
treatment (CS group: 11.52.5 vs. 7.883; p<0.01. Acetaminophen group:
9.94.1 vs. 8.34.9; n.s.). CS functional improvement remained signiﬁcant
at month 9 after treatment supression conﬁrming the carry-over effect of
CS.
Conclusions: These results suggest that CS effectively reduces synovitis
and clinical symptoms of OA, though these effects are not observed with
acetaminophen. It also conﬁrms the results from the NIH-funded GAIT
study. Therefore, CS seems to be a more effective therapeutic tool than
analgesics for patients with OA and synovial inﬂammation. Its carry over
effect (also conﬁrmed in this study) and its well-recognized safety proﬁle,
provide additional clinical beneﬁts vs. acetaminophen.
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CLINICAL EFFICACY OF ALENDRONATE TREATMENT IN PATIENTS WITH
HIP OSTEOARTHRITIS: A 2-YEAR RANDOMIZED CONTROLLED TRIAL
T. Nishii, S. Tamura, T. Shiomi, T. Sakai, M. Takao, H. Yoshikawa,
N. Sugano. Osaka Univ. Med. Sch., Osaka, Japan
Purpose: Degeneration and loss of cartilage is the main pathogenesis of
hip and knee osteoarthritis, but periarticular bone alteration such as
subchondral bone changes and osteophyte formation also plays an
important role on disease progression and clinical symptom. Regulation of
those bone turnovers by antiresorptive drugs may be effective approach
for osteoarthritis treatment. Clinical trials of bisphosphonate treatments
have not been conducted in hip osteoarthritis. Our objectives were to
examine clinical efﬁcacy of alendronate treatment in hip osteoarthritis by
a 2-year randomized controlled study.
Methods: We prospectively enrolled 51patients with symptomatic hip
osteoarthritis who met the following criteria; the Kellgren-Lawrence (KL)
osteoarthritis grade of 2 or more on anteroposterior radiographs, age
between 30 and 90 years, and no history of bisphosphonate administra-
tion. All participants provided informed consent to the study which was
approved by the Institutional Review Board. The patients were randomly
assigned to either the alendronate group (alendronate 35mg/week and
calcium lactate 600mg/day) or the control group (calcium lactate 600mg/
day) for 2 years in 1:2 ratios. All patients were scheduled to receive the
following assessments; (1) WOMAC pain score and visual analogue score
(VAS) at 6-month intervals, (2) anteroposterior pelvic radiographs at 6-
month intervals, (3) biochemical markers of urinary NTX-I and CTX-II at 0,
6,12,24months, (4) DEXA of the hip at 0, 6,12,24months, and (5) MRI of the
hip at 0, 12 months. Between the alendronate and control groups, changesof the pain scores, NTX-I and CTX-II values, bone mineral density were
compared using Mann-Whitney test. Osteoarthritis progression and
change of bone marrow edema (BME) on MRI were compared using
Fisher's exact test. Osteoarthritis progression was deﬁned as worsening of
joint space narrowing on radiographs or conversion to total hip arthro-
plasty. If the patient had osteoarthritis in both hips, only one hip withmore
severe osteoarthritis was included.
Results: Thirty-three patients in the alendronate group and 18 patients in
the control group were enrolled. During the follow-up, 8 patients were
excluded due to abdominal discomfort and transfer of the residence, and
remaining 30 patients in the alendronate group and 13 patients in the
control group were analyzed. At the entry, there were no signiﬁcant
differences of age, gender, BMI, KL grades, VAS, urinary NTX-I and CTX-II
values between the two groups. At 24 months, VAS pain reduction was
signiﬁcantly better in the alendronate group (p<0.05). Radiographic
osteoarthritis progression was seen in 14 hips (47%) of the alendronate
group and in 5 hips (38%) in the control group, without signiﬁcant
difference. NTX-I values were signiﬁcantly lower at all times, and CTX-II
values were signiﬁcantly lower at 24 months in the alendronate group (Fig
1). Among each group, however, therewas no signiﬁcant difference of CTX-
II values between the hips with and without osteoarthritis progression. On
MRI, the alendronate group showed higher frequency of BME reduction at
12 moths (31%), as compared with 0% in the control group.
Conclusions: Alendronate treatment had clinical efﬁcacy of pain reduction
but failed to show preventing effect of hip osteoarthritis progression.
These ﬁndings were in accordance with previous clinical trials of
bisphosphonate treatment in knee osteoarthritis. In knee osteoarthritis,
early reduction of CTX-II by bisphosphonate treatment was assumed
a prognostic index for prevention of osteoarthritis progression, however,
those associations were not found in hip osteoarthritis. Further investi-
gations regarding development of potent surrogates for disease progres-
sion and detection of optimal responders of bisphosphonate treatments
are required.
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SAFETY AND EFFICACY PROFILE OF NANO-FORMULATED, LOWER DOSE
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
V. Strand 1, R. Altman 2, S. Daniels 3, G. Manvelian 4. 1 Stanford Univ., Palo
Alto, CA, USA; 2UCLA Med. Ctr. RHU, Los Angeles, CA, USA; 3 Premier Res.
Group Limited, Clin. Res. Ctrs., Austin, TX, USA; 4 Iroko Pharmaceuticals,
Philadelphia, PA, USA
Purpose: NSAIDs are routinely prescribed for musculoskeletal conditions
including arthritis. Safety and tolerability, a common concernwith NSAIDs,
have shown to be dose-dependent. We present the safety and efﬁcacy of
investigational, nano-formulated, lower dose, oral NSAIDs (diclofenac,
indomethacin, and naproxen) in an established acute pain model.
Methods: All 3 Phase 2 trials were multi-center, randomized, double-
blind, single-dose, parallel-group, active- and placebo-controlled studies.
More than 200 subjects (N¼202 [diclofenac], N¼203 [indomethacin], and
N¼253 [naproxen]) were enrolled for each trial. Subjects were 18-50 years
of age, had extraction of 2 third molars (1 had to be a fully or partially
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pain intensity 6 hours after surgery. Subjects received a single dose of
nano-formulated, lower dose diclofenac, indomethacin, or naproxen, an
active comparator (parent compound or celecoxib), or placebo. Safety and
tolerability were assessed by examining the treatment-emergent adverse
events (TEAE) for each treatment compared with placebo. The primary
efﬁcacy endpoints were sum of total pain relief (TOTPAR) 0 to 12 hours
(diclofenac and naproxen) and 0 to 8 hours (indomethacin.)
Results: Safety and tolerability for all nano-formulated NSAIDs and
comparator treatments, as determined by the number of subjects of 1
severe TEAE, were similar when compared with placebo. Overall, TEAEs
occurred less frequently for nano-formulated diclofenac (18 mg and 35
mg) than they did with celecoxib 400 mg. The proportion of subjects with
1 severe TEAE was 0% (0/49), 3.9% (2/51), 2.0% (1/51), and 7.8% (4/51) for
nano-formulated diclofenac 18 mg, 35 mg, celecoxib 400 mg, and placebo,
respectively. TEAEs occurred less frequently in nano-formulated indo-
methacin 20 mg and 40 mg compared with placebo. The proportion of
subjects with 1 severe TEAE was 1.0% (2/50), 1.0% (2/51), 5.9% (3/51), and
5.9% (3/51) for nano-formulated indomethacin 20 mg, 40 mg, celecoxib
400 mg, and placebo, respectively. For nano-formulated naproxen, TEAEs
occurred less frequently for both nano-formulated naproxen doses (200
mg and 400 mg) compared with placebo. The proportion of subjects with
1 severe TEAE was 2.0% (1/51), 0% (0/51), 2.0% (1/50), 2.0% (1/50), and 0%
(0/51) for nano-formulated naproxen 200 mg, 400 mg, standard naproxen
250 mg, 500 mg, and placebo, respectively.
ĂThe nano-formulated NSAIDs achieved the primary efﬁcacy endpoints by
exhibiting statistically signiﬁcant improvements (P<0.001) in TOTPAR-8 or
-12 compared with placebo. For nano-formulated diclofenac and nano-
formulated naproxen, TOTPAR values were numerically better than the
active comparators. However, these studies were not powered to assess
statistical differences.
Conclusions: Investigational, nano-formulated, lower dose, oral NSAIDs
demonstrated comparable safety and tolerability, as well as efﬁcacy, in an
established acute pain model. These Phase 2 data suggest that nano-
formulated diclofenac, indomethacin, and naproxen may offer efﬁcacy at
a lower dose and better tolerability and deserve further investigation in
Phase 3 clinical trials. The aforementioned results are in line with the FDA
directive to use the lowest effective NSAID dose.
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BASELINE AND LONGITUDINAL PATTERNS OF NSAID USE FOR
SYMPTOMATIC KNEE OSTEOARTHRITIS: THE OAI
C.B. Eaton 1, J.B. Driban 2, M.B. Roberts 3, K.L. Lapane 4, M. Nevitt 5,
T.E. McAlindon 2. 1Warren Alpert Med. Sch. of Brown Univ., Providence, RI,
USA; 2 Tufts Med. Ctr., Boston, MA, USA; 3Mem. Hosp. of Rhode Island,
Pawtucket, RI, USA; 4Virginia Commonwealth Univ., Richmond, VA, USA;
5Univ. of California at San Francisco, San Francisco, CA, USAPurpose:Pharmacokinetic studies andclinical trials demonstrate that regular
use of NSAIDs are needed for its anti-inﬂammatory properties to be effective
in the treatment of knee osteoarthritis. However regular use of NSAIDs are
associatedwith increased rates of GI toxicity and cardiovascular disease. Thus
the FDA issued black box warning labels regarding these risks and suggested
that doctors and patients use NSAIDS at the lowest possible dose and
frequency to achieve clinical beneﬁt. We were interested in describing the
range of use of NSAIDs in participants with symptomatic knee osteoarthritis
and predictors of its baseline use, changes in patterns of use over time.
Methods: NSAID use was determined based upon questionnaire regarding
self-report and medication inventory requiring participants to bring in all
their prescription bottles . NSAID use was divided into three categories:
non use, OTC or infrequent use, regular use. Polytomous regression anal-
ysis was performed to predict categories of use at baseline using backward
selection models.
Results: 1172 participants with symptomatic knee OA were indentiﬁed in
the OAI study at baseline. Non use of NSAIDS was found in 722 (61.6%), 356
(30.4%) infrequent use and 94(8%) regular use. Regular users were more
likely than none users to be obese (aOR¼1.80, 95% CI 1.13-2.88), have
worse SF-12 physical function scores (aOR¼ 0.97, 95% CI 0.95-0.99), and
trends for worse WOMAC pain (aOR¼ 1.03, 95%CI 0.97-1.11, higher rates of
a history of knee surgery (aOR¼1.55, 95%CI 0.99-2.41), and concomitant
CAM therapy(aOR¼1.42,95%CI 0.90-2.23). Infrequent NSAID users
compared to non users were more likely to have worse SF-12 mental
health scores (aOR¼0.98, 0.97-0.99), worse WOMAC pain scores
(aOR¼1.05, 95%CI 1.01-1.09),and more CAM therapy use (aOR¼1.32, 95% CI
1.01-1.74). Regular users only differed from infrequent users by obesity
status (aOR¼ 1.89, 95% CI 1.16-3.09). Patterns of use are shown in the ﬁgure
below. Over 48 months of follow-up, nearly 2/3 of non users stayed non
users, while only a 1/3 of infrequent users stayed infrequent users , and
only 25% of frequent users stayed frequent users.
Conclusions: Regular NSAID use for symptomatic knee OA is modest (<
10%) in this study and is associated with obesity, worse physical func-
tioning while infrequent use is associated with worse mental health, and
more CAM therapy. Over four years of follow-up non users remained
relatively constant while infrequent and frequent users changed cate-
gories. Understanding the reasons for lack of use of NSAIDS and changing
patterns may inform better patient centered outcomes research.
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A PROPRIETARY, NANO-FORMULATED, LOWER DOSE ORAL NAPROXEN
PROVIDES EFFECTIVE PAIN RELIEF
R. Altman 1, S. Daniels 2, G. Manvelian 3. 1UCLA Med. Ctr. RHU, Los Angeles,
CA, USA; 2 Premier Res. Group Limited, Clin. Res. Ctrs., Austin, TX, USA; 3 Iroko
Pharmaceuticals, Philadelphia, PA, USA
Purpose: Naproxen is commonly prescribed for the relief of musculo-
skeletal conditions including arthritis. Naproxen, like other NSAIDs, has
the potential for serious adverse events (AEs). NSAID AEs have demon-
strated to be dose-dependent. Our objective was to evaluate the analgesic
